Resultados de la búsqueda 211-220 of 10226 for Cycle

1. Neurología - Ensayos clínicos

   ... cycle, if necessary delayed until all clinical parameters are acceptable to proceed with the next planned cycle of therapy; (3) if patient is completing non ...

2. Neurología - Ensayos clínicos

   ... cycle, if necessary delayed until all clinical parameters are acceptable to proceed with the next planned cycle of therapy; (3) if patient is completing non ...

3. Programa de tumores cerebrales - Ensayos clínicos

   ... cycle, if necessary delayed until all clinical parameters are acceptable to proceed with the next planned cycle of therapy; (3) if patient is completing non ...

4. Oncología (médica) - Ensayos clínicos

   ... cycles of mosunetuzumab. An additional arm (open to non-US participants only) has been added to assess the safety, tolerability, pharmacokinetics, and ...

5. Neurología - Ensayos clínicos

   ... cycle, if necessary delayed until all clinical parameters are acceptable to proceed with the next planned cycle of therapy; (3) if patient is completing non ...

6. Sangrado vaginal - Mayo Clinic

   Your menstrual cycle. Office on Women's Health. https://www.womenshealth.gov/menstrual-cycle/your-menstrual-cycle. Accessed Jan. 24, 2023. Goodman A ...

7. Neurología - Ensayos clínicos

   ... cycle, if necessary delayed until all clinical parameters are acceptable to proceed with the next planned cycle of therapy; (3) if patient is completing non ...

8. Programa de tumores cerebrales - Ensayos clínicos

   ... cycle, if necessary delayed until all clinical parameters are acceptable to proceed with the next planned cycle of therapy; (3) if patient is completing non ...

9. Oncología (médica) - Ensayos clínicos

   All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there ...

10. Ensayos clínicos - Neurología

    The purpose of this study is to assess the safety, tolerability, and effectiveness of additional 6-week treatment cycles with Rozanolixizumab in study ...